In this regard, SELENOP levels are elevated in T2D patients, and excessive SELENOP causes insulin resistance and also impairs the function of pancreatic β-cells, suggesting excessive SELENOP as a promising therapeutic target in T2D patients [58,59,60,61]. The gene discussed is SELENOP; the disease is Insulin resistance.